Effects of valeryl salicylate, a COX-1 inhibitor, on models of acute inflammation in mice

Pharmacological Research

Volumn 48, Issue 5, 2003, Pages 437-443

  Siqueira Junior, Jarbas M ^a   Peters, Rodrigo R ^a,b   De Brum Fernandes, Artur J ^c   Ribeiro Do Valle, Rosa M ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^c UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

COX 1; Mice; Paw oedema; Valeryl salicylate

Indexed keywords

ARACHIDONIC ACID; CARRAGEENAN; CELECOXIB; CROTON OIL; CYCLOOXYGENASE 1 INHIBITOR; INDOMETACIN; UNCLASSIFIED DRUG; VALERYL SALICYLATE;

ACCURACY; ANIMAL MODEL; APONEUROSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; INFLAMMATION; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; SURFACE PROPERTY;

EID: 0042829122     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00188-9     Document Type: Article

References (34)

1. Bhattacharyya D.K., Lecomte M., Dunn J., Morgans D.J., Smith W.L. Selective inhibition of prostaglandins endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. Arch. Biochem. Biophys. 317(1):1995;19-24.
2. van Ryn J., Trummlitz G., Pairet M. COX-2 selectivity and inflammatory process. Curr. Med. Chem. 7:2000;1145-1161.
3. DeWitt D.L., Smith W.L. Primary structure of prostaglandin G/H synthetase from sheep vesicular gland determined from the complementary DNA sequence. Proc. Natl. Acad. Sci. USA. 85:1988;1412-1416.
4. Funk C.D., Funk L.B., Kennedy M.E., Pong A.S., Fitzgerald G.A. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning expression and gene chromosomal assignment. FASEB J. 9:1991;2304-2312.
5. O'Neill G.P., Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330(2):1993;156-160.
6. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W.et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA. 91(25):1994;12013-12017.
7. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A.et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. USA. 95:1998;13313-13318.
8. DeWitt D.L., el-Harith E.A., Kraemer S.A., Andrews M.J., Yao E.F., Armstrong R.L.et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem. 265(9):1990;5192-5198.
9. Xie W.L., Chipman J.G., Robertson D.L., Erikson R.L., Simons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthetase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA. 88:1991;2692-2696.
10. O'Banion M.K., Winn V., Young D.A. cDNA cloning and functional activity of glucocoticoid-regulated inflammation cyclooxygenase. Proc. Natl. Acad. Sci. USA. 89:1992;4888-4892.
11. Hla T., Nielson K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA. 89:1992;7384-7388.
12. Smith W.L., DeWitt D.L. Differential interaction of prostaglandin endoperoxide synthases with nonsteroidal anti-inflammatory drugs. Curr. Opin. Invest. Drugs. 3:1994;1-11.
13. Hemple S.L., Monick M.M., Hunninghake G.W. Lipopolysaccharide induces prostaglandin H syntethase2 protein and mRNA in human alveolar macrophages and blood monocytes. J. Clin. Invest. 93:1994;391-396.
14. Harris R.C., McKanna J.A., Akai Y., Jacobson H.R., Dubois R.N., Breyer M.D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 94(6):1994;2504-2510.
15. Chan C.C. Pharmacology of a selective cyclooxygenase 2-inhibitor, L-745, 337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 274:1995;1531-1537.
16. Vane J.R. Inhibition of prostaglandins synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 231:1971;232-235.
17. DeWitt D.L. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim. Biophys. Acta. 1083(2):1991;121-134.
18. Gierse J.K., Hauser S.D., Creely D.P., Koboldt C., Ranqwala S.H., Isakson P.C.et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 305(Pt 2):1995;479-484.
19. Bateman D.N. NSAIDs: time to re-evaluate gut toxicity. Lancet. 343:1994;1051-1052.
20. Chan C.C., Gordon R., Brideau C., Rodger I.W., Li S., Prasit P.et al. In vivo pharmacology of L-745,337: a novel non-steroidal anti-inflammatory agent (NSAID) with an ulcerogenic sparing effect in rat and monkey stomach. Can. J. Physiol. Pharmacol. 72(Suppl. 1):1994;266.
21. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G.et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA. 91:1994;3228-3232.
22. Lane N.E. Pain management in osteoarthritis: the role of COX2 inhibitors. J. Rheumatol. 24:1997;20-24.
23. Bjarnason I., Macpherson A., Rotman H., Schupp J., Hayllar J. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase 2 inhibitor, flosulide, and naproxen. Scand. J. Gastroenterol. 32:1997;126-130.
24. Rao T.S., Currie J.L., Shaffer A.F., Isakson P.C. Comparative evaluation of arachidonic acid (AA)- and tetradecanoylphorbol acetate (TPA)-induced dermal inflammation. Inflammation. 17(6):1993;723-741.
25. Zhang Y., Shaffer A., Portanova J., Seibert K., Isakson P.C. Inhibition of cyclooxygenase2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J. Pharmacol. Exp. Ther. 283:1997;1069-1075.
26. Gilroy D.W., Tomlinson A., Willoughby D.A. Differential effects of inhibitors of cyclooxygenase (COX-1 and COX-2) in chronic inflammation. Inflamm. Res. 47:1998;79-85.
27. Wallace J.L., Chapman K., McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br. J. Pharmacol. 126:1999;1200-1204.
28. Ochi T., Goto T. Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis. Br. J. Pharmacol. 135:2002;782-788.
29. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C.et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83(3):1995;483-492.
30. Higgs G.A., Eakins K.E., Mugridge K.G., Moncada S., Vane J.R. The effects of non-steroidal anti-inflammatory drugs on leukocyte migration in carrageenan-induced inflammation. Eur. J. Pharmacol. 66:1980;81-86.
31. Hurley JV. Endogenous chemical mediators of inflammation. Acute inflammation, 2nd ed., London: Churchill Livingstone; 1983. p. 102-8.
32. Henriques M.G., Silva P.M., Martins M.A., Flores C.A., Cunha F.Q., Assreuy-Filho J.et al. Mouse paw edema. A new model for inflammation? Braz. J. Med. Biol. Res. 20(2):1987;243-249.
33. Nantel F., Denis D., Gordon R., Northey A., Cirino M., Metters K.M.et al. Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation. Br. J. Pharmacol. 128(4):1999;853-859.
34. Zhang J., Goorha S., Raghow R., Ballou L.R. The tissue-specific, compensatory expression of cyclooxygenase-1 and -2 in transgenic mice. Prostaglandins Other Lipid Mediat. 67(2):2002;121-135.